Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib

[thumbnail of 10901-Article Text-79832-2-10-20230427.pdf]
Preview

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Bye, A. P. ORCID: https://orcid.org/0000-0002-2061-2253, Kriek, N., Sage, T., Rawlings, S. J., Prodger, C., Kesavan, M., Lees, C., Booth, S., Cowen, L. G., Shefferd, K., Desborough, M. J., Gibbins, J. M. ORCID: https://orcid.org/0000-0002-0372-5352 and Eyre, T. A. (2023) Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib. Haematologica, 108 (5). ISSN 0390-6078 doi: 10.3324/haematol.2022.281402

Altmetric Badge

Dimensions Badge

Item Type Article
URI https://reading-pure-test.eprints-hosting.org/id/eprint/110390
Identification Number/DOI 10.3324/haematol.2022.281402
Refereed Yes
Divisions Life Sciences > School of Biological Sciences > Biomedical Sciences
Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy
Central Services
Download/View statistics View download statistics for this item
[thumbnail of 10901-Article Text-79832-2-10-20230427.pdf]
Preview
Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Downloads

Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record